{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:54:10Z","timestamp":1793091250091,"version":"4.5.0"},"reference-count":279,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T00:00:00Z","timestamp":1617062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Vaccination was first pioneered in the 18th century by Edward Jenner and eventually led to the development of the smallpox vaccine and subsequently the eradication of smallpox. The impact of vaccination to prevent infectious diseases has been outstanding with many infections being prevented and a significant decrease in mortality worldwide. Cancer vaccines aim to clear active disease instead of aiming to prevent disease, the only exception being the recently approved vaccine that prevents cancers caused by the Human Papillomavirus. The development of therapeutic cancer vaccines has been disappointing with many early cancer vaccines that showed promise in preclinical models often failing to translate into efficacy in the clinic. In this review we provide an overview of the current vaccine platforms, adjuvants and delivery systems that are currently being investigated or have been approved. With the advent of immune checkpoint inhibitors, we also review the potential of these to be used with cancer vaccines to improve efficacy and help to overcome the immune suppressive tumor microenvironment.<\/jats:p>","DOI":"10.3389\/fimmu.2021.627932","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T02:59:00Z","timestamp":1617073140000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":191,"title":["Cancer Vaccines, Adjuvants, and Delivery Systems"],"prefix":"10.3389","volume":"12","author":[{"given":"Samantha J.","family":"Paston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria A.","family":"Brentville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Symonds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindy G.","family":"Durrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.02.002","article-title":"Strategies to use immune modulators in therapeutic vaccines against cancer","volume":"39","author":"Berzofsky","year":"2012","journal-title":"Semin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.06.008","article-title":"Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations","volume":"43","author":"Parchment","year":"2016","journal-title":"Semin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/BF01246677","article-title":"Structure, chromosomal localization, and expression of 12 genes of the MAGE family","volume":"40","author":"De Plaen","year":"1994","journal-title":"Immunogenetics"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.5.1914","article-title":"A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening","volume":"94","author":"Chen","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7","article-title":"Characterization of the GAGE genes that are expressed in various human cancers and in normal testis","volume":"59","author":"De Backer","year":"1999","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.3.689","article-title":"A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma","volume":"182","author":"Van den Eynde","year":"1995","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(95)80053-0","article-title":"BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes","volume":"2","author":"Boel","year":"1995","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.180.1.35","article-title":"A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas","volume":"180","author":"Coulie","year":"1994","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3515","article-title":"Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor","volume":"91","author":"Kawakami","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.14.6458","article-title":"Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection","volume":"91","author":"Kawakami","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1084\/jem.178.2.489","article-title":"The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas","volume":"178","author":"Brichard","year":"1993","journal-title":"J Exp Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.10.3166","article-title":"Human prostate-specific antigen: structural and functional similarity with serine proteases","volume":"83","author":"Watt","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112185","article-title":"A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein","volume":"76","author":"Lilja","year":"1985","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.neo.7900201","article-title":"Deregulated expression of the human tumor marker CEA and CEA family member CEACAM6 disrupts tissue architecture and blocks colonocyte differentiation","volume":"4","author":"Ilantzis","year":"2002","journal-title":"Neoplasia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2014.04.007","article-title":"Carcinoembryonic antigen promotes colorectal cancer progression by targeting adherens junction complexes","volume":"324","author":"Bajenova","year":"2014","journal-title":"Exp Cell Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000055396","article-title":"Biology of HER2 and its importance in breast cancer","volume":"61","author":"Yarden","year":"2001","journal-title":"Oncology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80538-3","article-title":"hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization","volume":"90","author":"Meyerson","year":"1997","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0686","article-title":"The universal character of the tumor-associated antigen survivin","volume":"13","author":"Andersen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.14670\/HH-17.669","article-title":"Survivin\u2013a universal tumor antigen","volume":"17","author":"Andersen","year":"2002","journal-title":"Histol Histopathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.5.1921","article-title":"Prognostic significance of survivin expression in diffuse large B-cell lymphomas","volume":"96","author":"Adida","year":"2000","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-08-2554","article-title":"Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells","volume":"102","author":"Schmidt","year":"2003","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1309\/9R6673QEC06D86Y4","article-title":"Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study","volume":"122","author":"Lau","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"B27","article-title":"Expression of the Wilms\u2019 tumor gene (WT1) in human leukemias","volume":"6","author":"Miwa","year":"1992","journal-title":"Leukemia"},{"key":"B28","article-title":"Recursive partitioning as an approach to selection of immune markers for tumor diagnosis","volume":"9","author":"Koziol","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0538","article-title":"T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease","volume":"11","author":"Suzuki","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)91524-7","article-title":"Virus Particles in Cultured Lymphoblasts from Burkitt\u2019s Lymphoma","volume":"1","author":"Epstein","year":"1964","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa023141","article-title":"Characteristics of Hodgkin\u2019s lymphoma after infectious mononucleosis","volume":"349","author":"Hjalgrim","year":"2003","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/2281056a0","article-title":"EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx","volume":"228","author":"zur Hausen","year":"1970","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Munoz","year":"2003","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1186","article-title":"Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention","volume":"21","author":"Chu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B36","article-title":"NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin Cancer Res"},{"key":"B37","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J Natl Cancer Inst"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.8122112","article-title":"Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma","volume":"263","author":"Morris","year":"1994","journal-title":"Science"},{"key":"B41","article-title":"Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3","volume":"9","author":"Shiota","year":"1994","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2014.09.019","article-title":"ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma","volume":"26","author":"Bresler","year":"2014","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nature07398","article-title":"Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma","volume":"455","author":"Janoueix-Lerosey","year":"2008","journal-title":"Nature"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01718","article-title":"The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy","volume":"8","author":"Karpanen","year":"2017","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1515\/BC.2009.070","article-title":"Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice","volume":"390","author":"Ryan","year":"2009","journal-title":"Biol Chem"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0903852106","article-title":"Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy","volume":"106","author":"Depontieu","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B48","doi-asserted-by":"publisher","first-page":"203ra125","DOI":"10.1126\/scitranslmed.3006061","article-title":"MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia","volume":"5","author":"Cobbold","year":"2013","journal-title":"Sci Transl Med"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1085","article-title":"Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity","volume":"76","author":"Brentville","year":"2016","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0043","article-title":"MHC-restricted phosphopeptides from insulin receptor substrate-2 and CDC25b offer broad-based immunotherapeutic agents for cancer","volume":"74","author":"Zarling","year":"2014","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.12.1755","article-title":"Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo","volume":"192","author":"Zarling","year":"2000","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0604045103","article-title":"Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy","volume":"103","author":"Zarling","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000262","article-title":"MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma","volume":"8","author":"Engelhard","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.4161\/cc.6.6.4035","article-title":"Oncogenic transformation by the signaling adaptor proteins insulin receptor substrate (IRS)-1 and IRS-2","volume":"6","author":"Dearth","year":"2007","journal-title":"Cell Cycle"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00260-06","article-title":"Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2","volume":"26","author":"Dearth","year":"2006","journal-title":"Mol Cell Biol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14715\/cmb\/2017.63.1.1","article-title":"The role of insulin receptor substrate (IRS) proteins in oncogenic transformation","volume":"63","author":"Gorgisen","year":"2017","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M303535200","article-title":"Synergistic promotion of c-Src activation and cell migration by Cas and AND-34\/BCAR3","volume":"278","author":"Riggins","year":"2003","journal-title":"J Biol Chem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3455","article-title":"Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling","volume":"67","author":"Schrecengost","year":"2007","journal-title":"Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-16-0034","article-title":"Downregulation of the Deiminase PADI2 Is an Early Event in Colorectal Carcinogenesis and Indicates Poor Prognosis","volume":"14","author":"Cantarino","year":"2016","journal-title":"Mol Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000560","article-title":"Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses","volume":"8","author":"Brentville","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.2174\/1389450116666150202160954","article-title":"Protein Arginine Deiminases and Associated Citrullination: Physiological Functions and Diseases Associated with Dysregulation","volume":"16","author":"Witalison","year":"2015","journal-title":"Curr Drug Targets"},{"key":"B62","doi-asserted-by":"publisher","first-page":"7592851","DOI":"10.1155\/2019\/7592851","article-title":"An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders","volume":"2019","author":"Alghamdi","year":"2019","journal-title":"J Immunol Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20110640","article-title":"Autophagy in antigen-presenting cells results in presentation of citrullinated peptides to CD4 T cells","volume":"208","author":"Ireland","year":"2011","journal-title":"J Exp Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/art.25059","article-title":"Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis","volume":"62","author":"Feitsma","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00494","article-title":"Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted alpha-Enolase T Cell Epitope in Rheumatoid Arthritis","volume":"7","author":"Gerstner","year":"2016","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01236","article-title":"Corrigendum: Functional and Structural Characterization of a Novel HLA-DRB1*04:01-Restricted alpha-Enolase T Cell Epitope in Rheumatoid Arthritis","volume":"8","author":"Gerstner","year":"2017","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/art.38637","article-title":"Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy","volume":"66","author":"James","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/art.30445","article-title":"Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1*0401-positive humanized mice and rheumatoid arthritis patients","volume":"63","author":"Snir","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e1171447","DOI":"10.1080\/2162402X.2016.1171447","article-title":"HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance","volume":"6","author":"Seliger","year":"2017","journal-title":"Oncoimmunology"},{"key":"B70","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90060-0","article-title":"Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma","volume":"29","author":"Coppola","year":"1998","journal-title":"Hum Pathol"},{"key":"B72","article-title":"Clinical significance of vimentin-positive gastric cancer cells","volume":"30","author":"Fuyuhiro","year":"2010","journal-title":"Anticancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199610)180:2<175::AID-PATH630>3.0.CO;2-G","article-title":"Vimentin expression in cervical carcinomas: association with invasive and migratory potential","volume":"180","author":"Gilles","year":"1996","journal-title":"J Pathol"},{"key":"B74","article-title":"Cytokeratin expression and vimentin content in large cell anaplastic lymphomas and other non-Hodgkin\u2019s lymphomas","volume":"138","author":"Gustmann","year":"1991","journal-title":"Am J Pathol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1472-6890-9-9","article-title":"CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma","volume":"9","author":"Williams","year":"2009","journal-title":"BMC Clin Pathol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19921101)70:9<2326::AID-CNCR2820700919>3.0.CO;2-D","article-title":"An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma. Recognition of lethal and favorable prognostic types","volume":"70","author":"Yamamoto","year":"1992","journal-title":"Cancer"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1258\/ebm.2011.010367","article-title":"Strategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells","volume":"236","author":"Palena","year":"2011","journal-title":"Exp Biol Med (Maywood)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1021\/bi00220a034","article-title":"Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor","volume":"30","author":"Miles","year":"1991","journal-title":"Biochemistry"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24355","article-title":"An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen","volume":"125","author":"Cappello","year":"2009","journal-title":"Int J Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-015-0117-5","article-title":"Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K\/AKT pathway","volume":"8","author":"Fu","year":"2015","journal-title":"J Hematol Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3572","article-title":"Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells","volume":"6","author":"Principe","year":"2015","journal-title":"Oncotarget"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3639","article-title":"Enolase-1 is a therapeutic target in endometrial carcinoma","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/art.23936","article-title":"Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase","volume":"58","author":"Lundberg","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e1576490","DOI":"10.1080\/2162402X.2019.1576490","article-title":"T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy","volume":"8","author":"Brentville","year":"2019","journal-title":"Oncoimmunology"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e1390642","DOI":"10.1080\/2162402X.2017.1390642","article-title":"Citrullinated alpha-enolase is an effective target for anti-cancer immunity","volume":"7","author":"Cook","year":"2018","journal-title":"Oncoimmunology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2016.1166326","article-title":"Autophagy, citrullination and cancer","volume":"12","author":"Durrant","year":"2016","journal-title":"Autophagy"},{"key":"B87","doi-asserted-by":"publisher","first-page":"101393","DOI":"10.1016\/j.smim.2020.101393","article-title":"Post-translational modifications such as citrullination are excellent targets for cancer therapy","volume":"47","author":"Brentville","year":"2020","journal-title":"Semin Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00449-4","article-title":"Dendritic cells: specialized and regulated antigen processing machines","volume":"106","author":"Mellman","year":"2001","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1400478111","article-title":"Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants","volume":"111","author":"Maisonneuve","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/ni1059","article-title":"Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance","volume":"5","author":"Yang","year":"2004","journal-title":"Nat Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nature12978","article-title":"Structure-based programming of lymph-node targeting in molecular vaccines","volume":"507","author":"Liu","year":"2014","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.09.010","article-title":"Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs","volume":"146","author":"Ammi","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/BF00205743","article-title":"Phase-I study of intravenous modified lipid A","volume":"18","author":"Vosika","year":"1984","journal-title":"Cancer Immunol Immunother"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/9.Supplement_5.S512","article-title":"Characterization of a nontoxic monophosphoryl lipid A","volume":"9","author":"Johnson","year":"1987","journal-title":"Rev Infect Dis"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0631696100","article-title":"Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7","volume":"100","author":"Lee","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535806","article-title":"Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T-rich phosphorothiate oligodeoxynucleotides","volume":"36","author":"Jurk","year":"2006","journal-title":"Eur J Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U","article-title":"Identification of CpG oligonucleotide sequences with high induction of IFN-alpha\/beta in plasmacytoid dendritic cells","volume":"31","author":"Krug","year":"2001","journal-title":"Eur J Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2000.00964.x","article-title":"CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12","volume":"99","author":"Kranzer","year":"2000","journal-title":"Immunology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2064","article-title":"Agonistic CD40 antibodies and cancer therapy","volume":"19","author":"Vonderheide","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.11.071","article-title":"Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity","volume":"28","author":"McWilliams","year":"2010","journal-title":"Vaccine"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2089","article-title":"CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations","volume":"77","author":"Nimanong","year":"2017","journal-title":"Cancer Res"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1177\/2051013613501988","article-title":"Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants","volume":"1","author":"Dubensky","year":"2013","journal-title":"Ther Adv Vaccines"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/nature07317","article-title":"STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling","volume":"455","author":"Ishikawa","year":"2008","journal-title":"Nature"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0123","article-title":"STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer","volume":"2","author":"Chandra","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41467-017-00573-w","article-title":"Signalling strength determines proapoptotic functions of STING","volume":"8","author":"Gulen","year":"2017","journal-title":"Nat Commun"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1172\/JCI79915","article-title":"Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants","volume":"125","author":"Hanson","year":"2015","journal-title":"J Clin Invest"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300097","article-title":"Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid","volume":"190","author":"Conlon","year":"2013","journal-title":"J Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e83765","DOI":"10.1371\/journal.pone.0083765","article-title":"Combined stimulation of IL-2 and 4-1BB receptors augments the antitumor activity of E7 DNA vaccines by increasing Ag-specific CTL responses","volume":"8","author":"Kim","year":"2013","journal-title":"PLoS One"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602019","article-title":"A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer","volume":"91","author":"Pavlenko","year":"2004","journal-title":"Br J Cancer"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0802982","article-title":"IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity","volume":"182","author":"Sikora","year":"2009","journal-title":"J Immunol"},{"key":"B115","first-page":"895s","article-title":"Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12","volume":"7","author":"Gajewski","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.18.3836","article-title":"Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma","volume":"19","author":"Lee","year":"2001","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-065X.2002.18813.x","article-title":"GM-CSF-based cancer vaccines","volume":"188","author":"Dranoff","year":"2002","journal-title":"Immunol Rev"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0757","article-title":"High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells","volume":"64","author":"Serafini","year":"2004","journal-title":"Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1544","article-title":"Effect of granulocyte\/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial","volume":"15","author":"Slingluff","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/bs.ai.2015.12.001","article-title":"Advances in Therapeutic Cancer Vaccines","volume":"130","author":"Wong","year":"2016","journal-title":"Adv Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"174378","DOI":"10.1155\/2010\/174378","article-title":"DNA vaccines: developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"J BioMed Biotechnol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1115\/1.2768380","article-title":"Local temperature rises influence in vivo electroporation pore development: a numerical stratum corneum lipid phase transition model","volume":"129","author":"Becker","year":"2007","journal-title":"J Biomech Eng"},{"key":"B123","doi-asserted-by":"publisher","first-page":"e7226","DOI":"10.1371\/journal.pone.0007226","article-title":"Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment","volume":"4","author":"Roos","year":"2009","journal-title":"PLoS One"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.11.1645","article-title":"Electroporation of skeletal muscle induces danger signal release and antigen-presenting cell recruitment independently of DNA vaccine administration","volume":"8","author":"Chiarella","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1586\/erv.10.42","article-title":"Electroporation for DNA immunization: clinical application","volume":"9","author":"van Drunen Littel-van den Hurk","year":"2010","journal-title":"Expert Rev Vaccines"},{"key":"B126","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2016.05.004","article-title":"DNA vaccines to attack cancer: Strategies for improving immunogenicity and efficacy","volume":"165","author":"Tiptiri-Kourpeti","year":"2016","journal-title":"Pharmacol Ther"},{"key":"B127","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-1-4939-2727-2_2","article-title":"Gene Gun Her2\/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2\/neu Mouse Tumor Model","volume":"1317","author":"Nguyen-Hoai","year":"2015","journal-title":"Methods Mol Biol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(03)00275-5","article-title":"Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe","volume":"21","author":"Trimble","year":"2003","journal-title":"Vaccine"},{"key":"B129","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.addr.2015.12.024","article-title":"Nanotechnology inspired tools for mitochondrial dysfunction related diseases","volume":"99","author":"Wen","year":"2016","journal-title":"Adv Drug Delivery Rev"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1039\/C5BM00161G","article-title":"A7RC peptide modified paclitaxel liposomes dually target breast cancer","volume":"3","author":"Cao","year":"2015","journal-title":"Biomater Sci"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1039\/c3tb21423k","article-title":"Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo","volume":"2","author":"Li","year":"2014","journal-title":"J Mater Chem B"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.16.9","article-title":"Recent advances in liposome surface modification for oral drug delivery","volume":"11","author":"Nguyen","year":"2016","journal-title":"Nanomed (Lond)"},{"key":"B133","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0005-2736(99)00023-1","article-title":"Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells","volume":"1418","author":"Pires","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"B134","doi-asserted-by":"publisher","first-page":"39475","DOI":"10.1038\/srep39475","article-title":"Central Role of CD169(+) Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01","volume":"6","author":"Detienne","year":"2016","journal-title":"Sci Rep"},{"key":"B135","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B137","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bip.21328","article-title":"Self-assembly of peptide amphiphiles: from molecules to nanostructures to biomaterials","volume":"94","author":"Cui","year":"2010","journal-title":"Biopolymers"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1039\/C4OB00447G","article-title":"Self-assembly of peptides to nanostructures","volume":"12","author":"Mandal","year":"2014","journal-title":"Org Biomol Chem"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912124107","article-title":"A self-assembling peptide acting as an immune adjuvant","volume":"107","author":"Rudra","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.4155\/tde.11.68","article-title":"Subunit vaccines of the future: the need for safe, customized and optimized particulate delivery systems","volume":"2","author":"Foged","year":"2011","journal-title":"Ther Deliv"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","article-title":"Pathogen recognition and development of particulate vaccines: does size matter","volume":"40","author":"Xiang","year":"2006","journal-title":"Methods"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/nmat3775","article-title":"Engineering synthetic vaccines using cues from natural immunity","volume":"12","author":"Irvine","year":"2013","journal-title":"Nat Mater"},{"key":"B143","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2018.07.001","article-title":"PEGylated enhanced cell penetrating peptide nanoparticles for lung gene therapy","volume":"285","author":"Osman","year":"2018","journal-title":"J Control Release"},{"key":"B144","doi-asserted-by":"publisher","first-page":"119277","DOI":"10.1016\/j.biomaterials.2019.119277","article-title":"Highly versatile cell-penetrating peptide loaded scaffold for efficient and localised gene delivery to multiple cell types: From development to application in tissue engineering","volume":"216","author":"Raftery","year":"2019","journal-title":"Biomaterials"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1518634113","article-title":"Highly efficient delivery of functional cargoes by the synergistic effect of GAG binding motifs and cell-penetrating peptides","volume":"113","author":"Dixon","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2016.06.004","article-title":"Highly efficient intracellular transduction in three-dimensional gradients for programming cell fate","volume":"41","author":"Eltaher","year":"2016","journal-title":"Acta Biomater"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2017.04.028","article-title":"Controlled release of GAG-binding enhanced transduction (GET) peptides for sustained and highly efficient intracellular delivery","volume":"57","author":"Abu-Awwad","year":"2017","journal-title":"Acta Biomater"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1002\/sctm.17-0137","article-title":"Osteogenic Programming of Human Mesenchymal Stem Cells with Highly Efficient Intracellular Delivery of RUNX2","volume":"6","author":"Thiagarajan","year":"2017","journal-title":"Stem Cells Transl Med"},{"key":"B149","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13287-018-1123-7","article-title":"Ex vivo MRI cell tracking of autologous mesenchymal stromal cells in an ovine osteochondral defect model","volume":"10","author":"Markides","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.004469","article-title":"Discovery of peptide ligands targeting a specific ubiquitin-like domain-binding site in the deubiquitinase USP11","volume":"294","author":"Spiliotopoulos","year":"2019","journal-title":"J Biol Chem"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/356152a0","article-title":"Genetic immunization is a simple method for eliciting an immune response","volume":"356","author":"Tang","year":"1992","journal-title":"Nature"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1126\/science.8456302","article-title":"Heterologous protection against influenza by injection of DNA encoding a viral protein","volume":"259","author":"Ulmer","year":"1993","journal-title":"Science"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.9.4156","article-title":"Gene inoculation generates immune responses against human immunodeficiency virus type 1","volume":"90","author":"Wang","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00238-4","article-title":"Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine","volume":"20","author":"Kojima","year":"2002","journal-title":"Vaccine"},{"key":"B156","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.158.8.3635","article-title":"Contribution of CpG motifs to the immunogenicity of DNA vaccines","volume":"158","author":"Klinman","year":"1997","journal-title":"J Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1035502","article-title":"DNA vaccines, electroporation and their applications in cancer treatment","volume":"11","author":"Lee","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"B159","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.addr.2016.08.005","article-title":"The design of peptide-amphiphiles as functional ligands for liposomal anticancer drug and gene delivery","author":"Kuang","year":"2017","journal-title":"Adv Drug Deliv Rev"},{"key":"B160","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4161\/mabs.1.1.7492","article-title":"Antibodies designed as effective cancer vaccines","volume":"1","author":"Metheringham","year":"2009","journal-title":"MAbs"},{"key":"B161","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1002\/eji.200939857","article-title":"DNA vaccination with T-cell epitopes encoded within Ab molecules induces high-avidity anti-tumor CD8+ T cells","volume":"40","author":"Pudney","year":"2010","journal-title":"Eur J Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e41112","DOI":"10.1371\/journal.pone.0041112","article-title":"High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment","volume":"7","author":"Brentville","year":"2012","journal-title":"PLoS One"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13070","article-title":"SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors","volume":"7","author":"Xue","year":"2016","journal-title":"Oncotarget"},{"key":"B164","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/eji.201343863","article-title":"Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice","volume":"44","author":"Saif","year":"2014","journal-title":"Eur J Immunol"},{"key":"B165","doi-asserted-by":"publisher","first-page":"e1433516","DOI":"10.1080\/2162402X.2018.1433516","article-title":"Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I\/II trial","volume":"7","author":"Patel","year":"2018","journal-title":"Oncoimmunology"},{"key":"B166","article-title":"Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors","volume":"1","author":"Lu","year":"1994","journal-title":"Cancer Gene Ther"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2006.06.024","article-title":"Cationic lipids, lipoplexes and intracellular delivery of genes","volume":"116","author":"Wasungu","year":"2006","journal-title":"J Control Release"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0403549101","article-title":"Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines","volume":"101","author":"Little","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.12.029","article-title":"Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format","volume":"166","author":"Phua","year":"2013","journal-title":"J Control Release"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1021\/mp100390w","article-title":"In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles","volume":"8","author":"Su","year":"2011","journal-title":"Mol Pharm"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31815ce501","article-title":"Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA","volume":"31","author":"Weide","year":"2008","journal-title":"J Immunother"},{"key":"B172","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide","year":"2009","journal-title":"J Immunother"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.289","article-title":"Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients","volume":"19","author":"Rittig","year":"2011","journal-title":"Mol Ther"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"B176","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/gt.2009.122","article-title":"Partial protection against SIV challenge by vaccination of adenovirus and MVA vectors in rhesus monkeys","volume":"17","author":"Wang","year":"2010","journal-title":"Gene Ther"},{"key":"B177","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1038\/s41598-018-21630-4","article-title":"Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP","volume":"8","author":"Bliss","year":"2018","journal-title":"Sci Rep"},{"key":"B178","volume-title":"W.H.o., The COVID-19 candidate vaccine landscape and tracker","year":"2021"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e3182325e63","article-title":"Viral vector-based therapeutic cancer vaccines","volume":"17","author":"Larocca","year":"2011","journal-title":"Cancer J"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.10.206","article-title":"Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas","volume":"23","author":"Marshall","year":"2005","journal-title":"J Clin Oncol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.10.041","article-title":"Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates","volume":"29","author":"Capone","year":"2010","journal-title":"Vaccine"},{"key":"B182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-4-1","article-title":"A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer","volume":"4","author":"DiPaola","year":"2006","journal-title":"J Transl Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.7748","article-title":"Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer","volume":"35","author":"Kantoff","year":"2017","journal-title":"J Clin Oncol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02031","article-title":"Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer","volume":"37","author":"Gulley","year":"2019","journal-title":"J Clin Oncol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"h988","DOI":"10.1136\/bmj.h988","article-title":"Cancer vaccines","volume":"350","author":"Butterfield","year":"2015","journal-title":"BMJ"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0374","article-title":"Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8(+) T Cells","volume":"5","author":"Zahm","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2017.06.004","article-title":"Identification of B and T cell epitope based peptide vaccine from IGF-1 receptor in breast cancer","volume":"75","author":"Mahdavi","year":"2017","journal-title":"J Mol Graph Model"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"B189","doi-asserted-by":"publisher","first-page":"e974411","DOI":"10.4161\/2162402X.2014.974411","article-title":"Trial Watch: Peptide-based anticancer vaccines","volume":"4","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"key":"B190","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev Res (Phila)"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2614","article-title":"MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer","volume":"17","author":"Morse","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0233","article-title":"Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival","volume":"21","author":"Reed","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B193","article-title":"Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate","volume":"45","author":"Sands","year":"1994","journal-title":"Mol Pharmacol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"e40208","DOI":"10.1371\/journal.pone.0040208","article-title":"Antibody-antigen-adjuvant conjugates enable co-delivery of antigen and adjuvant to dendritic cells in cis but only have partial targeting specificity","volume":"7","author":"Kreutz","year":"2012","journal-title":"PLoS One"},{"key":"B195","doi-asserted-by":"publisher","first-page":"e947892","DOI":"10.4161\/21624011.2014.947892","article-title":"Two in one: improving synthetic long peptide vaccines by combining antigen and adjuvant in one molecule","volume":"3","author":"Zom","year":"2014","journal-title":"Oncoimmunology"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0223","article-title":"Efficient induction of antitumor immunity by synthetic toll-like receptor ligand-peptide conjugates","volume":"2","author":"Zom","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11512","article-title":"TLR2 ligand-synthetic long peptide conjugates effectively stimulate tumor-draining lymph node T cells of cervical cancer patients","volume":"7","author":"Zom","year":"2016","journal-title":"Oncotarget"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.7.4373","article-title":"Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines","volume":"174","author":"Heit","year":"2005","journal-title":"J Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.7676","article-title":"Immunization with HIV-1 Gag protein conjugated to a TLR7\/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses","volume":"174","author":"Wille-Reece","year":"2005","journal-title":"J Immunol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1382-6","article-title":"BiVax: a peptide\/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses","volume":"62","author":"Cho","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B201","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1021\/acs.bioconjchem.7b00808","article-title":"Toll-like Receptor Agonist Conjugation: A Chemical Perspective","volume":"29","author":"Ignacio","year":"2018","journal-title":"Bioconjug Chem"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01044","article-title":"Synthesis and Evaluation of Novel TLR2 Agonists as Potential Adjuvants for Cancer Vaccines","volume":"63","author":"Lu","year":"2020","journal-title":"J Med Chem"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0390-x","article-title":"Peptide-TLR-7\/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens","volume":"38","author":"Lynn","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines2030515","article-title":"Peptide Vaccine: Progress and Challenges","volume":"2","author":"Li","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e318233e5b2","article-title":"The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination","volume":"17","author":"Slingluff","year":"2011","journal-title":"Cancer J"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.01.018","article-title":"Multi-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies","volume":"27","author":"Chianese-Bullock","year":"2009","journal-title":"Vaccine"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-018-0028-2","article-title":"A facile approach to enhance antigen response for personalized cancer vaccination","volume":"17","author":"Li","year":"2018","journal-title":"Nat Mater"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1038\/nmat4822","article-title":"Designer vaccine nanodiscs for personalized cancer immunotherapy","volume":"16","author":"Kuai","year":"2017","journal-title":"Nat Mater"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2009.10.002","article-title":"Recent developments in liposomes, microparticles and nanoparticles for protein and peptide drug delivery","volume":"31","author":"Tan","year":"2010","journal-title":"Peptides"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.7150\/thno.20118","article-title":"Preparation and Application of Cell Membrane-Camouflaged Nanoparticles for Cancer Therapy","volume":"7","author":"Zhai","year":"2017","journal-title":"Theranostics"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1039\/C8BM00466H","article-title":"Immunomodulatory vasoactive intestinal peptide amphiphile micelles","volume":"6","author":"Zhang","year":"2018","journal-title":"Biomater Sci"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3105","article-title":"Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion","volume":"19","author":"Hailemichael","year":"2013","journal-title":"Nat Med"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507484102","article-title":"HIV Gag protein conjugated to a Toll-like receptor 7\/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates","volume":"102","author":"Wille-Reece","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03222-1","article-title":"Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis","volume":"76","author":"Jin","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B216","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-018-0825-x","article-title":"LncRNAs regulate the cytoskeleton and related Rho\/ROCK signaling in cancer metastasis","volume":"17","author":"Tang","year":"2018","journal-title":"Mol Cancer"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17648","article-title":"Role of tumor microenvironment in tumorigenesis","volume":"8","author":"Wang","year":"2017","journal-title":"J Cancer"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.385","article-title":"BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM","volume":"118","author":"Wei","year":"2018","journal-title":"Br J Cancer"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.7150\/jca.30222","article-title":"Herpesvirus acts with the cytoskeleton and promotes cancer progression","volume":"10","author":"Wu","year":"2019","journal-title":"J Cancer"},{"key":"B220","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13578-019-0289-8","article-title":"Communication between mitochondria and other organelles: a brand-new perspective on mitochondria in cancer","volume":"9","author":"Xia","year":"2019","journal-title":"Cell Biosci"},{"key":"B221","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.4110\/in.2013.13.5.184","article-title":"Emerging Co-signaling Networks in T Cell Immune Regulation","volume":"13","author":"Jung","year":"2013","journal-title":"Immune Netw"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401686","article-title":"Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo","volume":"194","author":"Das","year":"2015","journal-title":"J Immunol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"B230","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B231","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/2326-6066.CIR-14-0126","article-title":"Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication","volume":"4","author":"Ali","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2564","article-title":"Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody","volume":"74","author":"Karyampudi","year":"2014","journal-title":"Cancer Res"},{"key":"B233","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/annonc\/mdx686","article-title":"Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy","volume":"29","author":"Rotte","year":"2018","journal-title":"Ann Oncol"},{"key":"B234","doi-asserted-by":"publisher","first-page":"857519","DOI":"10.1155\/2013\/857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1695","article-title":"Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines","volume":"76","author":"Bakdash","year":"2016","journal-title":"Cancer Res"},{"key":"B237","doi-asserted-by":"publisher","first-page":"e1169353","DOI":"10.1080\/2162402X.2016.1169353","article-title":"SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade","volume":"5","author":"Xue","year":"2016","journal-title":"Oncoimmunology"},{"key":"B238","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1084\/jem.20062056","article-title":"Induced sensitization of tumor stroma leads to eradication of established cancer by T cells","volume":"204","author":"Zhang","year":"2007","journal-title":"J Exp Med"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.12.7516","article-title":"Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor","volume":"174","author":"Lugade","year":"2005","journal-title":"J Immunol"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1126\/science.1253462","article-title":"Spatial and temporal diversity in genomic instability processes defines lung cancer evolution","volume":"346","author":"de Bruin","year":"2014","journal-title":"Science"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat Genet"},{"key":"B242","doi-asserted-by":"publisher","first-page":"283ra54","DOI":"10.1126\/scitranslmed.aaa1408","article-title":"Clonal status of actionable driver events and the timing of mutational processes in cancer evolution","volume":"7","author":"McGranahan","year":"2015","journal-title":"Sci Transl Med"},{"key":"B243","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B244","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat8549","article-title":"Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8(+) T cell responses","volume":"11","author":"Zamora","year":"2019","journal-title":"Sci Transl Med"},{"key":"B246","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/icb.2013.29","article-title":"Myeloid-derived suppressor cells in cancer: recent progress and prospects","volume":"91","author":"Khaled","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"B249","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ccr.2007.12.004","article-title":"Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis","volume":"13","author":"Yang","year":"2008","journal-title":"Cancer Cell"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1508-5","article-title":"Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab","volume":"63","author":"Meyer","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B251","doi-asserted-by":"publisher","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"key":"B252","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","article-title":"Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis","volume":"5","author":"Shang","year":"2015","journal-title":"Sci Rep"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-018-0011-0","article-title":"A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy","volume":"28","author":"Du","year":"2018","journal-title":"Cell Res"},{"key":"B256","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1784","article-title":"Selective Targeting of Myeloid-Derived Suppressor Cells in Cancer Patients Using DS-8273a, an Agonistic TRAIL-R2 Antibody","volume":"23","author":"Dominguez","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.04.016","article-title":"Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression","volume":"19","author":"Schmid","year":"2011","journal-title":"Cancer Cell"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B259","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","article-title":"Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing","volume":"9","author":"Bartoschek","year":"2018","journal-title":"Nat Commun"},{"key":"B260","article-title":"Cancer associated fibroblasts: the dark side of the coin","volume":"1","author":"Cirri","year":"2011","journal-title":"Am J Cancer Res"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2013.05.004","article-title":"\u2018Cancer associated fibroblasts\u2019\u2013more than meets the eye","volume":"19","author":"Madar","year":"2013","journal-title":"Trends Mol Med"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2014-202561","article-title":"Importance of carcinoma-associated fibroblast-derived proteins in clinical oncology","volume":"67","author":"Valcz","year":"2014","journal-title":"J Clin Pathol"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140692","article-title":"Fibroblast heterogeneity in the cancer wound","volume":"211","author":"Ohlund","year":"2014","journal-title":"J Exp Med"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2013.01.018","article-title":"Fibroblast-mediated drug resistance in cancer","volume":"85","author":"Paraiso","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20130110","article-title":"Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia","volume":"210","author":"Tran","year":"2013","journal-title":"J Exp Med"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27553","article-title":"Contribution of regulatory T cells to cancer: A review","volume":"234","author":"Najafi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27665","article-title":"CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice","volume":"61","author":"Chen","year":"2015","journal-title":"Hepatology"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(93)90264-L","article-title":"Natural history of HLA expression during tumour development","volume":"14","author":"Garrido","year":"1993","journal-title":"Immunol Today"},{"key":"B271","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance","volume":"74","author":"Marincola","year":"2000","journal-title":"Adv Immunol"},{"key":"B272","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/scbi.2001.0404","article-title":"HLA class I antigen abnormalities and immune escape by malignant cells","volume":"12","author":"Seliger","year":"2002","journal-title":"Semin Cancer Biol"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(01)83005-0","article-title":"MHC antigens and tumor escape from immune surveillance","volume":"83","author":"Garrido","year":"2001","journal-title":"Adv Cancer Res"},{"key":"B274","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0167-5699(96)10075-X","article-title":"Implications for immunosurveillance of altered HLA class I phenotypes in human tumours","volume":"18","author":"Garrido","year":"1997","journal-title":"Immunol Today"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1084\/jem.191.6.961","article-title":"Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer","volume":"191","author":"Koopman","year":"2000","journal-title":"J Exp Med"},{"key":"B276","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-3-030-17864-2_2","article-title":"MHC\/HLA Class I Loss in Cancer Cells","volume":"1151","author":"Garrido","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05173-4","article-title":"Loss of HER2 after HER2-targeted treatment","volume":"175","author":"Ignatov","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.6963","article-title":"Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma","volume":"28","author":"Sampson","year":"2010","journal-title":"J Clin Oncol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200405000-00002","article-title":"Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression","volume":"27","author":"Khong","year":"2004","journal-title":"J Immunother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.627932\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T06:33:49Z","timestamp":1698129229000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.627932\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,30]]},"references-count":279,"alternative-id":["10.3389\/fimmu.2021.627932"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.627932","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,30]]},"article-number":"627932"}}